Unicel dxi 800 access immunoassay system

Demographics and clinical characteristics of each participant were collected at the time of enrollment, including age, gender, primary diseases, body mass index (BMI), hypertension, diabetes mellitus, smoking history (>10 cigarettes per day lasting for 5 years or more), dialysis duration, Kt/V, and MAP. Blood samples were collected from MHD participants in the morning after overnight fast before midweek dialysis sessions for biochemical measurement. The serum hemoglobin (Hb) level was determined by using an automated hematology analyzer (Sysmex XN-9000, Japan), and the levels of creatinine, blood urea nitrogen (BUN), uric acid (UA), albumin, calcium, phosphate, ALP, total cholesterol (TC), triglycerides (TG), LDL cholesterol (LDL-C), HDL cholesterol (HDL-C), hs-CRP by using standard autoanalyzer techniques (Beckman AU5800), and the intact parathyroid hormone (iPTH) by using a UniCel DxI 800 Access Immunoassay System (Beckman Coulter, Inc., Fullerton, CA, USA) were also determined.

After completing the Morris Water maze experiment, all rats were euthanized and blood was collected from right atrium to detect serum levels of thiamin, folic acid and homocysteine. Serum thiamin and folic acid were detected on LK3000VI vitamin detector (Tianjin Lanbiao, China) and UniCel DxI 800 Access Immunoassay System (Beckman Coulter, USA) respectively. Homocysteine level was detected on Hitachi 7600-020 automatic biochemical analyzer (Hitachi, Japan).

In all biomarker assays, the laboratory technicians were blinded to the clinical status (GDM or not) of study subjects. Cord plasma FABP4 was measured by an ELISA kit (R&D systems, Minnesota, USA). Plasma estradiol was measured by an ELISA kit (Labor Diagnostika Nord, Germany). Plasma testosterone was measured by a chemiluminescence immunoassay kit on a UniCel DXI 800 Access Immunoassay System (Beckman Coulter, USA). The detection limits were 6.55 pg/mL for FABP4, 6.2 pg/mL for estradiol, and 0.35 nmol/L for testosterone, respectively. The intra-assay and inter-assay coefficients of variation were in the ranges of 3.4-12.7% for FABP4, 3.1-6.4% for estradiol, and 1.7-7.1% for testosterone, respectively.
As reported previously, cord plasma leptin was measured by an ELISA kit from Invitrogen (Carlsbad, CA, USA), total and high-molecular-weight (HMW) adiponectin by an ELISA kit from ALPCO (Salem, NH, USA) (26 (link)). The intra-assay and inter-assay coefficients of variation were in the range of 6.9-10.4% (26 (link)).

Serum estradiol and progesterone concentrations were determined by automated competitive chemiluminescent immunoassays (Ref No.: B84493 and 33550) on the Beckman Coulter UniCel DxI 800 Access Immunoassay System (Beckman Coulter, Inc., Brea, CA 92821, U.S.A.). Serum 25-hydroxyvitamin D levels were measured by an automated competitive electrochemiluminescent assay (Ref No.: 09038086190) on the e 801 module of a Cobas 8000 analyzer (Roche Diagnostics GmbH, Mannheim, Germany).

The patients’ clinical information was collected from the case report forms of the study. Medical history data included age, menstrual status, ECOG score, past medical history, biochemical parameters and the parameters of routine blood tests. Other treatment information included chemotherapy, radiotherapy, and targeted therapy. Pathological results were reported by two different pathologists independently and included pathological type, tumour size, histological grade, lymph node involvement, ER expression, progesterone receptor (PR) expression, CerbB-2 status and the result of the fluorescence in situ hybridization (FISH) test. ER or PR positivity was defined as nuclear staining in more than 1% of tumour cells. Tumours with a CerbB-2 3+ status in the immunohistochemistry assay and/or human epidermal growth factor receptor-2 (HER-2) gene overexpression confirmed by FISH were defined as HER-2 positive.
Serum oestradiol (E2), follicle-stimulating hormone (FSH) and luteinizing hormone (LH) were measured at baseline and every 3 months after randomization by the gynecological clinical Lab in our hospital. Hormone levels were analyzed using commercially available kits from the Unicel DXI 800 Access immunoassay system (Beck-man Coulter).

CA15-3 levels were assayed by using the Vitros-3600 system (Ortho-Clinical Diagnostics; Rochester, NY, USA) with Vitros Immunodiagnostic Products CA15-3 (Ortho-Clinical Diagnostics). Tests for CEA were performed using the UniCel DxI 800 Access Immunoassay System with the CEA test kit (Beckman Coulter Inc.; Brea, CA, USA). Each assay was performed according to the respective manufacturer's instructions based on chemiluminescent reactions.